Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype.
about
KASL clinical practice guidelines: management of chronic hepatitis BManagement of chronic hepatitis B infection: current treatment guidelines, challenges, and new developmentsTreatment strategies according to genotype for chronic hepatitis B in childrenLong-term effect of interferon plus ribavirin on hepatitis B surface antigen seroclearance in patients dually infected with hepatitis B and C viruses.Precise prediction model and simplified scoring system for sustained combined response to interferon-alpha.Effect of hepatitis B virus genotypes on the efficacy of adefovir dipivoxil antiviral therapy.Safety and efficacy of oral HD-03/ES given for six months in patients with chronic hepatitis B virus infectionEvaluation of the Abbott HBV RUO sequencing assay combined with laboratory-modified interpretive softwareSystematic review of the literature on comparative effectiveness of antiviral treatments for chronic hepatitis B infection.Hepatobiliary quiz 11 (2014)Susceptibility of different hepatitis B virus isolates to interferon-alpha in a mouse model based on hydrodynamic injectionHBV and HCV therapy.Molecular epidemiology of hepatitis B virus.Hepatitis B virus genotypes and variants.KASL Clinical Practice Guidelines: Management of chronic hepatitis B.Safety and efficacy of two-step peginterferon α-2a treatment in patients of chronic hepatitis B with acute exacerbationChronic hepatitis B in children in the United States and Canada: international origins place the disease burden on children even in the era of universal vaccinationRecommendations and potential future options in the treatment of hepatitis B.Immunopathogenesis of hepatitis B virus infection.Hepatitis B and D viruses replication interference: Influence of hepatitis B genotype.Future prospectives for the management of chronic hepatitis B.Molecular testing in the diagnosis and management of chronic hepatitis BVirologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach.Role of viral factors in the natural course and therapy of chronic hepatitis B.Hepatitis B virus genotypes: natural history and implications for treatment.Hepatitis B therapy in children.Chronic hepatitis B: who to treat and which choice of treatment?Hepatitis B virus genotyping: is the time ripe for routine clinical use?Hepatobiliary quiz-3 (2012)Monotherapy versus combination therapy for the treatment of chronic hepatitis B.Hepatitis B virus genotypes among chronic hepatitis B patients reporting at Korle-Bu teaching hospital, Accra, Ghana.Entecavir for the long-term treatment of chronic hepatitis B.Correlation between the suppressor of cytokine signaling-1 and 3 and hepatitis B virus: possible roles in the resistance to interferon treatment.Molecular methods in the diagnosis and management of chronic hepatitis B.Antiviral drugs for HBV liver disease.Hepatitis B surface antigen monitoring and management of chronic hepatitis B.Is there any value to hepatitis B virus genotype analysis?Considerations for the long-term treatment of chronic hepatitis B with nucleos(t)ide analogs.The role of HBsAg quantification for monitoring natural history and treatment outcome.HBV genotype B/C and response to lamivudine therapy: a systematic review
P2860
Q26752475-2CB3E27A-304A-4DE4-A996-6A4B9C87B1CDQ27008984-63D13B7B-0528-433A-983A-1DDB4D4D00E3Q28066476-65E44F60-6BB8-4A46-9230-77FAF2473E57Q33939443-6938B101-A0E6-4504-8757-A47849E286B8Q33998692-0B728B1C-5CB5-4579-B971-594C9761B993Q34196714-823ED955-9551-4399-8944-40F46AC0C3E3Q34382110-B2349F4D-5705-4D21-A03A-11213D2B354CQ34458149-09598FB6-B389-4B15-8ECE-2997BCB266BBQ34594403-688132DB-0684-4500-B0C7-ABC9452A0D97Q34825710-60662EB6-78B2-43DE-BEF4-4F8C3711365EQ35117727-F64402C6-62B5-4A36-A4EF-6A4DB7EC3BDCQ35259824-7425C541-E980-430D-8C94-9A6F30ED4202Q35331524-5D3B2064-656E-47A0-88D1-F348CC7EDD01Q35663838-D5263349-E131-4786-AC12-A9A8739C3EABQ36153966-8E179A8F-29E0-458F-9009-5AF7B6D4C04BQ36371537-419C527A-9769-452D-AF58-9CF2304CFAC1Q36508484-F3A73721-934C-4E0E-813A-C99B8E3FAD37Q36632233-24AD0AA4-D50F-412E-8004-D3F92E3F6014Q36666336-70E136F5-8650-4ABE-A957-ECAFAEBA2C81Q36682594-1725747F-1B06-4427-B072-36F00A9BA6C9Q36841719-0D03ADDD-C37E-4D5A-AD15-CE374C217F10Q36881140-FFA77B1C-9B5C-472C-A601-CC7FBCBE5125Q37074608-31C4FB32-9E5B-4946-BD4B-7543F7CCDF00Q37280144-C4F544DA-20D0-4095-8787-E5F850DC2177Q37346012-13379DB0-B932-4345-9FF2-E77C74A59E9DQ37390647-D9623D8B-9F5C-4332-AF7A-6DFF464D0DE8Q37432086-ED539BCE-D45F-460E-9D8F-5C7166897D3AQ37613150-03FDF428-DA53-4BBF-85B4-AF1BCFEED1E0Q37613918-60C5F33D-9AA8-4ED2-AFE5-EAA08F34280FQ37620354-EA5B997A-3199-4F04-AA35-693692EEE9E3Q37624794-AD77C8EA-1D05-4192-8715-38D839D8C1A5Q37626058-D07FAB89-A8E4-4236-9815-79EF9EB2CD9EQ37716483-60B92D7E-1023-4134-8982-028DAF4B6337Q37801940-4B7F2B09-A4C3-4520-846C-86277CF9ED4FQ37825909-43CFFC36-9CFE-4E94-AE75-5AB85ECB7430Q37892655-F27193D9-9965-481C-B255-30A4367E3887Q37959290-252782AF-88A1-457F-9E51-87ACEF26C34CQ38067130-8CC291AB-1424-43D0-BB26-3DA2AD54EF93Q38071397-17651595-8CF1-4F60-A50B-B719AB21A302Q38173381-2411731E-5426-420E-82D6-624F71AD098E
P2860
Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Treatment with Peg-interferon ...... associated with HBV genotype.
@en
Treatment with Peg-interferon ...... associated with HBV genotype.
@nl
type
label
Treatment with Peg-interferon ...... associated with HBV genotype.
@en
Treatment with Peg-interferon ...... associated with HBV genotype.
@nl
prefLabel
Treatment with Peg-interferon ...... associated with HBV genotype.
@en
Treatment with Peg-interferon ...... associated with HBV genotype.
@nl
P2093
P2860
P1476
Treatment with Peg-interferon ...... associated with HBV genotype.
@en
P2093
HBV 99-01 Study Group
Hajo J Flink
Harry L A Janssen
Monika van Zonneveld
Robert A de Man
Solko W Schalm
P2860
P304
P356
10.1111/J.1572-0241.2006.00418.X
P407
P50
P577
2006-02-01T00:00:00Z